Regeneron stock: Q3 growth strengthens Sanofi partnership
Published on 11/05/2026 at 17:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegeneron expands growth platform
- Third-quarter revenue rose 36 percent as Sanofi collaboration revenue increased sharply.
- The expanded alliance adds four long-acting antibodies and a USD 1.0 billion upfront payment expected in fourth-quarter revenue.
- Higher EYLEA HD and Libtayo sales offset continued pressure on the older EYLEA franchise.
Regeneron Pharmaceuticals reported strong third-quarter results on Friday, October 30, 2026, while expanding its antibody alliance with Sanofi. The company's official third-quarter release said revenue for the period ended September 30 increased 36 percent year over year to USD 5.116 billion.
Growth broadens beyond Dupixent
GAAP net income rose 33 percent to USD 1.949 billion, while diluted GAAP earnings per share increased 35 percent to USD 18.45. Adjusted net income climbed 67 percent to USD 2.150 billion, lifting non-GAAP diluted earnings per share 70 percent to USD 20.07 from USD 11.83 a year earlier.
Sanofi collaboration revenue increased 68 percent to USD 2.724 billion. Regeneron's share of antibody commercialization profits reached USD 2.575 billion, compared with USD 1.456 billion in the year-earlier quarter, supported by higher Dupixent-related profits and the full repayment of Sanofi's development balance at the end of the second quarter.
Dupixent global sales recorded by Sanofi rose 35 percent to USD 6.541 billion. EYLEA HD sales increased 63 percent to USD 1.083 billion, while combined EYLEA and EYLEA HD sales declined 11 percent to USD 1.741 billion as patients continued to move from the older formulation. Libtayo sales advanced 51 percent to USD 550 million.
Sanofi deal adds pipeline depth
In October, Regeneron and Sanofi amended their collaboration to add four next-generation, long-acting antibodies invented by Regeneron. Regeneron received a USD 1.0 billion upfront payment that it expects to recognize as collaboration revenue in the fourth quarter of 2026, with up to an additional USD 7.0 billion tied to development, regulatory and sales milestones.
The partners will share development and commercialization costs equally and split future global profits equally if the programs reach the market. REGN20423 is in a Phase 1 study for atopic dermatitis, while the other three programs are expected to enter clinical studies in 2027. Regeneron also expects an FDA decision on cemdisiran in generalized myasthenia gravis in December.
Course remains below latest report
Regeneron stock traded at 820.55 euros on Lang & Schwarz at 17:30 CET on Thursday, November 5. This was 7.38 percent below the 885.95-euro quote in the latest relevant report published on November 4 at 14:41 CET. The real-time quote of Regeneron stock is available for investors tracking the next move.
Regeneron Pharmaceuticals at a glance
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Home exchange: Nasdaq
- Latest quote: 820.55 euros on Lang & Schwarz, Thursday, November 5, 2026 at 17:30 CET
- Third-quarter revenue: USD 5.116 billion, up 36 percent year over year
- Non-GAAP diluted EPS: USD 20.07, up 70 percent year over year
U.S. equities provide the relevant market backdrop for Regeneron through the S&P 500.
More news and analyses on Regeneron stock cover the company's pipeline, products and collaboration milestones.
